A new comprehensive analysis has revealed that major depressive disorder alters both the physical architecture and the ...

Patients with depressive symptoms and asthma had elevated levels of serum brain-derived neurotrophic factor in association ...

A new medical large language model (LLM) achieved over 91% accuracy in identifying female participants diagnosed with major ...

In the previous post, readers were reacquainted with the basics of major depressive disorder (MDD). Today, we will start looking at the subtypes, beginning with major depression with psychotic ...

Johnson & Johnson’s decision to splash out $14.6 billion on its purchase of Intra-Cellular Therapies earlier this year was largely driven by the acquired company's rising antipsychotic star Caplyta ...

A new medical large language model (LLM) achieved over 91 percent accuracy in identifying female participants diagnosed with ...

The U.S. Food and Drug Administration has approved Caplyta (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder in adults. This approval marks ...

The use of 42 mg lumateperone combined with antidepressant therapy was linked to significantly reduced severity of depression and anxiety, as well as greater response and remission rates, and was ...

The American College of Lifestyle Medicine, or ACLM, released a new expert consensus statement on the role of lifestyle ...

The consensus statement affirms that lifestyle interventions—optimal nutrition, physical activity, restorative sleep, stress management, connectedness, and avoidance of risky substances—are integral ...